AGREE-II scores for all domains and overall judgement for guideline use
| Guideline | Scope and purpose | Stakeholder involvement | Rigour of development | Clarity of presentation | Applicability | Editorial independence | Overall assessment |
| Scaled per cent | Scaled per cent | Scaled per cent | Scaled per cent | Scaled per cent | Scaled per cent | ||
| Acute lymphoblastic leukaemia | 77.8 | 42.6 | 61.8 | 85.2 | 36.1 | 94.4 | Recommend with improvement |
| Acute myeloid leukaemia | 79.6 | 38.9 | 59.0 | 87.0 | 40.3 | 94.4 | Recommend with improvement |
| Amyloidosis | 42.6 | 50.0 | 57.6 | 74.1 | 48.6 | 94.4 | Recommend with improvement |
| Anal | 72.2 | 37.0 | 54.9 | 81.5 | 40.3 | 94.4 | Recommend with improvement |
| B cell | 74.1 | 50.0 | 56.9 | 81.5 | 52.8 | 94.4 | Recommend with improvement |
| Basal cell | 77.8 | 53.7 | 61.8 | 85.2 | 62.5 | 94.4 | Recommend with improvement |
| Bladder | 74.1 | 42.6 | 57.6 | 90.7 | 51.4 | 94.4 | Recommend with improvement |
| Bone | 77.8 | 51.9 | 67.4 | 85.2 | 59.7 | 94.4 | Recommend with improvement |
| Breast | 79.6 | 50.0 | 70.8 | 79.6 | 62.5 | 94.4 | Recommend with improvement |
| Cervical | 68.5 | 51.9 | 63.9 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Chronic lymphocytic leukaemia | 83.3 | 51.9 | 57.6 | 83.3 | 65.3 | 94.4 | Recommend with improvement |
| Chronic myeloid Leukaemia | 70.4 | 40.7 | 65.3 | 87.0 | 45.8 | 94.4 | Recommend with improvement |
| Central nervous system | 77.8 | 53.7 | 58.3 | 81.5 | 66.7 | 94.4 | Recommend with improvement |
| Colon | 83.3 | 42.6 | 61.1 | 70.4 | 51.4 | 94.4 | Recommend with improvement |
| Cutaneous B cell | 63.0 | 50.0 | 43.8 | 77.8 | 61.1 | 94.4 | Recommend with improvement |
| Dermato-protuberans | 77.8 | 50.0 | 65.3 | 88.9 | 63.9 | 94.4 | Recommend with improvement |
| Esophageal | 81.5 | 50.0 | 66.0 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Gastric | 66.7 | 40.7 | 61.1 | 83.3 | 50.0 | 94.4 | Recommend with improvement |
| Hairy cell | 70.4 | 42.6 | 63.9 | 85.2 | 50.0 | 94.4 | Recommend with improvement |
| Head/neck | 74.1 | 51.9 | 65.3 | 81.5 | 65.3 | 94.4 | Recommend with improvement |
| Hepatobiliary | 77.8 | 48.1 | 64.6 | 83.3 | 59.7 | 94.4 | Recommend with improvement |
| Hodgkin | 70.4 | 42.6 | 68.1 | 87.0 | 52.8 | 94.4 | Recommend with improvement |
| Kaposi | 70.4 | 48.1 | 63.9 | 83.3 | 54.2 | 94.4 | Recommend with improvement |
| Kidney | 74.1 | 53.7 | 61.8 | 85.2 | 65.3 | 94.4 | Recommend with improvement |
| Myelodysplastic syndrome | 63.0 | 40.7 | 43.8 | 68.5 | 40.3 | 94.4 | Recommend with improvement |
| Melanoma | 72.2 | 51.9 | 62.5 | 81.5 | 61.1 | 94.4 | Recommend with improvement |
| Merkel | 68.5 | 48.1 | 65.3 | 85.2 | 61.1 | 94.4 | Recommend with improvement |
| Mesothelioma | 81.5 | 40.7 | 62.5 | 87.0 | 51.4 | 94.4 | Recommend with improvement |
| Myeloproliferative neoplasms | 79.6 | 53.7 | 59.0 | 85.2 | 55.6 | 94.4 | Recommend with improvement |
| Myeloma | 70.4 | 53.7 | 66.7 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Neuroendocrine | 74.1 | 46.3 | 67.4 | 87.0 | 69.4 | 94.4 | Recommend with improvement |
| Non-small-cell lung | 77.8 | 51.9 | 66.7 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Occult primary | 74.1 | 51.9 | 66.0 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Ovarian | 85.2 | 51.9 | 62.5 | 87.0 | 61.1 | 94.4 | Recommend with improvement |
| Pancreatic | 74.1 | 51.9 | 66.7 | 85.2 | 65.3 | 94.4 | Recommend with improvement |
| Penile | 72.2 | 53.7 | 68.1 | 87.0 | 63.9 | 94.4 | Recommend with improvement |
| Prostate | 81.5 | 46.3 | 67.4 | 85.2 | 56.9 | 94.4 | Recommend with improvement |
| Rectal | 70.4 | 53.7 | 63.9 | 87.0 | 66.7 | 94.4 | Recommend with improvement |
| Sarcoma | 75.9 | 53.7 | 61.8 | 87.0 | 58.3 | 94.4 | Recommend with improvement |
| Squamous cell | 74.1 | 53.7 | 66.7 | 85.2 | 62.5 | 94.4 | Recommend with improvement |
| Small-cell lung | 70.4 | 42.6 | 50.7 | 85.2 | 48.6 | 94.4 | Recommend with improvement |
| T cell | 75.9 | 44.4 | 62.5 | 85.2 | 50.0 | 94.4 | Recommend with improvement |
| Testicular | 74.1 | 53.7 | 64.6 | 87.0 | 69.4 | 94.4 | Recommend with improvement |
| Thymus | 77.8 | 46.3 | 64.6 | 87.0 | 52.8 | 94.4 | Recommend with improvement |
| Thyroid | 63.0 | 53.7 | 64.6 | 87.0 | 68.1 | 94.4 | Recommend with improvement |
| Uterine | 74.1 | 53.7 | 64.6 | 87.0 | 61.1 | 94.4 | Recommend with improvement |
| Vulvar | 79.6 | 42.6 | 63.9 | 85.2 | 51.4 | 94.4 | Recommend with improvement |
| Waldenstrom | 74.1 | 55.6 | 66.0 | 87.0 | 61.1 | 94.4 | Recommend with improvement |
| Average scaled domain score | 73.9 | 48.6 | 62.4 | 84.4 | 57.5 | 94.4 |
AGREE-II, Appraisal of Guidelines for Research and Evaluation.